

ULRR


The effect of resistance exercise training on anxiety symptoms: a systematic review and meta-analysis

| | |
|---------------|---------------------------------------------------------------------------------------------------------------------|
| Item Type | Meetings and Proceedings |
| Authors | Gordon, Brett R.;Lyons, Mark;Herring, Matthew P. |
| Citation | American College of Sports Medicine Annual Meeting; |
| Publisher | Wolters Kluwer |
| Download date | 2026-03-16 20:40:57 |
| Item License | https://creativecommons.org/licenses/by-nc-sa/1.0/ |
| Link to Item | https://hdl.handle.net/10344/5929 |

The Effect of Resistance Exercise Training on Anxiety Symptoms: A Systematic Review and Meta-Analysis

Gordon BR,¹ Lyons M,¹ & Herring MP^{1,2}

¹Department of Physical Education and Sport Sciences; ²Health Research Institute; University of Limerick, Limerick, Ireland



Abstract

Purpose: To estimate the population effect size for resistance exercise training (RET) effects on anxiety and to determine whether variables of logical, theoretical, and/or prior empirical relation to anxiety moderate the overall effect.

Methods: Thirty-one effects were derived from 16 articles published before February, 2017, located using Google Scholar, MEDLINE, PsycINFO, PubMed, and Web of Science. Trials involved 922 participants and included both randomization to RET (n=486) or a non-active control condition (n=436), and a validated anxiety outcome measured at baseline, mid- and/or post-intervention. Hedges' *d* effect sizes were computed and random effects models were used for all analyses. Meta-regression quantified the extent to which participant and trial characteristics moderated the mean effect.

Results: RET significantly reduced anxiety symptoms ($\Delta=0.31$, 95%CI: 0.17-0.44; $z=4.43$; $p<0.001$). Significant heterogeneity was not indicated ($Q(30)=40.5$, $p>0.09$; $I^2=28.3\%$, 95%CI: 10.17%-42.81%); sampling error accounted for 77.7% of observed variance. Larger effects were found among healthy participants ($\Delta=0.50$, 95%CI: 0.22-0.78) compared to participants with an illness ($\Delta=0.19$, 95%CI: 0.06-0.31, $z=2.16$, $p<0.04$). Effect sizes did not significantly vary according to sex ($\beta=-0.31$), age ($\beta=-0.10$), control condition ($\beta=0.08$), program length ($\beta=0.07$), session duration ($\beta=0.08$), frequency ($\beta=-0.10$), intensity ($\beta=-0.18$), anxiety recall time frame ($\beta=0.21$), or whether strength significantly improved ($\beta=0.19$) (all $p\geq 0.06$).

Conclusions: RET significantly improves anxiety symptoms among both healthy participants and participants with a physical or mental illness. Improvements were not moderated by sex, or based on features of RET. Future trials should compare RET to other empirically-supported therapies for anxiety.

Background

The available evidence supports the anxiolytic effects of acute exercise, and exercise training among otherwise healthy adults, adults with a chronic illness, and anxiety disorder patients.


Although aerobic exercise training has well-established effects on anxiety that are comparable to other empirically-supported treatments, the anxiolytic effects of RET remain understudied.

To date there has been no quantitative synthesis of the available empirical evidence, particularly randomized controlled trials.

Methods

Inclusion criteria were: (1) English language peer-reviewed publications, (2) randomized allocation to either an exercise intervention or a non-active control condition, and (3) an anxiety outcome measured at baseline and at mid- and/or post-intervention.

Investigations were excluded that (1) included exercise as one part of a multicomponent intervention but did not include the additional component in a comparison condition, and/or (2) compared exercise only with an active treatment.



Data Synthesis and Analysis

Hedges' *d* effect sizes were calculated by subtracting the mean change in the comparison condition from the mean change in the exercise condition, and dividing this difference by the pooled standard deviation of baseline scores.

Meta-regression was used as the overall analysis of moderator effects. Random effects models were used with macros (SPSS MeanES, MetaReg; SPSS, Inc) to aggregate mean effect size delta (Δ) and to test variation in effects according to moderator variables.

Moderators were selected based on theoretical, practical, and/or prior empirical relation with anxiety and/or exercise effects on anxiety.

Results

Twenty-seven of 31 effects (87.1%) were larger than zero.

The mean effect size Δ was 0.31 (95%CI: 0.17-0.44; $z=4.43$; $p<0.001$).

Significant heterogeneity was not indicated ($Q(30)=40.5$, $p>0.09$; $I^2=28.3\%$, 95%CI: 10.17%-42.81%), and sampling error accounted for 77.7% of observed variance.

The fail-safe number of effects was 151

Larger effects were derived from studies in which participants were healthy ($\Delta=0.50$, 95%CI: 0.22-0.78) compared to physically- or mentally-ill participants ($\Delta=0.19$, 95%CI: 0.06-0.31, $z=2.16$, $p<0.04$).

Effect sizes did not significantly vary according to sex ($\beta=-0.31$), age ($\beta=-0.10$), control condition ($\beta=0.08$), program length ($\beta=0.07$), session duration ($\beta=0.08$), frequency ($\beta=-0.10$), intensity ($\beta=-0.18$), supervision ($\beta=0.06$), primary outcome ($\beta=0.29$), recall ($\beta=0.21$), or a significant improvement in strength ($\beta=0.19$) (all $p\geq 0.07$).

Effects were similar for the RET interventions ($\Delta=0.13$, 95%CI: 0.03-0.29) and AET interventions ($\Delta=0.18$, 95%CI: 0.03-0.33).

When directly comparing the effects of RET to AET, with RET serving as the intervention group and AET serving as the control group in Hedges' *d* calculations, no significant differences were found ($\Delta=-0.07$, 95%CI: -0.22 to 0.09).

Univariate Moderator Analysis


| Effect moderator | Contrast weights | Effects (k) | Δ | 95% CI | Contrast <i>p</i> -value |
|--------------------------------------------|------------------|-------------|----------|---------------|--------------------------|
| Sex | | | | | |
| Female | -1 | 16 | 0.44 | 0.24 to 0.63 | 0.07 |
| Mixed | 0.5 | 10 | 0.11 | -0.06 to 0.27 | |
| Male | 0.5 | 5 | 0.43 | -0.11 to 0.96 | |
| Age(y) | | | | | |
| <25 | 0.5 | 10 | 0.31 | 0.11 to 0.51 | 0.56 |
| 25-54 | 0.5 | 8 | 0.26 | -0.03 to 0.55 | |
| 55+ | -1 | 12 | 0.40 | 0.13 to 0.66 | |
| Health | | | | | |
| Healthy | 1 | 13 | 0.50 | 0.22 to 0.78 | 0.03 |
| Physical illness | -0.5 | 10 | 0.15 | 0.02 to 0.29 | |
| Mental illness | -0.5 | 8 | 0.37 | 0.01 to 0.73 | |
| Control | | | | | |
| No treatment | 1 | 13 | 0.40 | 0.13 to 0.66 | 0.62 |
| Usual care | -0.5 | 6 | 0.12 | -0.08 to 0.32 | |
| Wait list | -0.5 | 10 | 0.41 | 0.16 to 0.67 | |
| Program | | | | | |
| <12 weeks | -1 | 14 | 0.28 | 0.18 to 0.50 | 0.68 |
| 12+ weeks | 1 | 15 | 0.42 | 0.15 to 0.70 | |
| Session | | | | | |
| <60min | -1 | 22 | 0.29 | 0.15 to 0.42 | 0.63 |
| 60+ min | 1 | 7 | 0.33 | -0.08 to 0.74 | |
| Frequency | | | | | |
| 2d/week | -1 | 8 | 0.41 | 0.13 to 0.70 | 0.56 |
| 3d/week | 1 | 21 | 0.34 | 0.17 to 0.54 | |
| Intensity | | | | | |
| Moderate | 1 | 24 | 0.31 | 0.14 to 0.47 | 0.27 |
| Vigorous | -1 | 6 | 0.47 | 0.14 to 0.80 | |
| Supervised | | | | | |
| Combination | -1 | 5 | 0.10 | -0.44 to 0.65 | 0.77 |
| Yes | 1 | 20 | 0.20 | 0.08 to 0.32 | |
| Primary Outcome | | | | | |
| Anxiety | | | | | |
| No | -1 | 8 | 0.16 | 0.01 to 0.31 | 0.07 |
| Yes | 1 | 23 | 0.42 | 0.22 to 0.61 | |
| State vs. Trait | | | | | |
| State | -1 | 22 | 0.27 | 0.12 to 0.43 | 0.17 |
| Trait | 1 | 9 | 0.42 | 0.16 to 0.69 | |
| Significant Improvement in Strength | | | | | |
| Yes | 1 | 21 | 0.37 | 0.20 to 0.54 | 0.24 |
| No | -0.5 | 2 | 0.18 | -0.07 to 0.43 | |
| Not reported | -0.5 | 8 | 0.20 | -0.17 to 0.56 | |

Participant & Trial Characteristics

| Study | Measure | Intensity | Duration(wk) | Participant characteristics | Control | Sex | Age(y) | Hedges' <i>d</i> (ES \pm 95%CI) |
|--------------------------|---------|-----------|----------------|-----------------------------|--------------|--------------|--------|-----------------------------------|
| Aidar et al. [25] | STAI-S | Moderate | 12 | Ischemic stroke | Usual care | Mixed | 43-60 | 0.26 (-0.55 to 1.06) |
| Aidar et al. [25] | STAI-T | Moderate | 12 | Ischemic stroke | Usual care | Mixed | 43-60 | 0.24 (-0.57 to 1.04) |
| Courneya et al. [30] | STAI-S | Moderate | Mid-treatment | Breast-cancer | Usual care | Female | 25-78 | 0.16 (-0.15 to 0.46) |
| Courneya et al. [30] | STAI-S | Moderate | Post-treatment | Breast-cancer | Usual care | Female | 25-78 | 0.08 (-0.23 to 0.38) |
| Damush et al. [33] | MHFI-A | Moderate | 8 | Elderly | Wait list | Female | 62-74 | 0.29 (-0.21 to 0.79) |
| Goldfield et al. [21] | BRUMS-T | Moderate | 22 | Obese adolescents | No treatment | Mixed | 14-18 | 0.14 (-0.18 to 0.46) |
| Herring et al. [26] | POMS-T | Moderate | 2 | GAD | Wait list | Female | 18-37 | 0.62 (-0.28 to 1.51) |
| Herring et al. [26] | STAI-T | Moderate | 2 | GAD | Wait list | Female | 18-37 | 0.14 (-0.74 to 1.02) |
| Herring et al. [26] | POMS-T | Moderate | 4 | GAD | Wait list | Female | 18-37 | 0.15 (-0.72 to 1.03) |
| Herring et al. [26] | STAI-T | Moderate | 4 | GAD | Wait list | Female | 18-37 | 0.36 (-0.52 to 1.25) |
| Herring et al. [26] | POMS-T | Moderate | 6 | GAD | Wait list | Female | 18-37 | 1.05 (0.12 to 1.99) |
| Herring et al. [26] | STAI-T | Moderate | 6 | GAD | Wait list | Female | 18-37 | 0.52 (-0.37 to 1.41) |
| Herring et al. [41] | HADS-A | Moderate | 12 | Morbidly obese | Usual care | Mixed | 24-68 | -0.49 (-1.47 to 0.49) |
| Lau et al. [20] | HADS-A | Vigorous | 6 | Obese adolescents | Usual care | Mixed | 10-17 | 0.41 (-0.25 to 1.07) |
| Martins et al. [22] | POMS-T | Moderate | 16 | Elderly | No treatment | Mixed | 65-95 | -0.34 (-0.89 to 0.20) |
| Norvell et al. [23] | SCL-90 | Moderate | 16 | Law enforcement personnel | Wait list | Male | 25-40 | 1.17 (0.38 to 1.96) |
| Nyberg et al. [32] | HADS-A | Moderate | 8 | COPD | Other | Mixed | 61-74 | 0.34 (-0.26 to 0.09) |
| O'Reilly et al. [39] | HADS-A | Low | 36 | People with knee pain | No treatment | Mixed | 40-80 | 0.14 (-0.15 to 0.43) |
| Rahmani-Nia et al. [39] | STAI-S | Moderate | 8 | Untrained college students | No treatment | Not reported | 20-23 | 0.43 (-0.19 to 1.06) |
| Rahmani-Nia et al. [39] | STAI-T | Moderate | 8 | Untrained college students | No treatment | Not reported | 20-23 | 0.32 (-0.30 to 0.95) |
| Tsutsumi et al. [28] | STAI-T | Moderate | 12 | Elderly | No treatment | Female | 60-86 | 1.50 (0.59 to 2.40) |
| Tsutsumi et al. [28] | STAI-S | Moderate | 12 | Elderly | No treatment | Female | 60-86 | 0.87 (0.03 to 1.70) |
| Tsutsumi et al. [28] | POMS-T | Moderate | 12 | Elderly | No treatment | Female | 60-86 | 0.63 (-0.19 to 1.45) |
| Tsutsumi et al. [28] | STAI-T | Vigorous | 12 | Elderly | No treatment | Female | 60-86 | 0.89 (0.05 to 1.73) |
| Tsutsumi et al. [28] | STAI-S | Vigorous | 12 | Elderly | No treatment | Female | 60-86 | 0.64 (-0.18 to 1.46) |
| Tsutsumi et al. [28] | POMS-T | Vigorous | 12 | Elderly | No treatment | Female | 60-86 | 0.85 (0.01 to 1.68) |
| Vizza et al. [31] | DASS-21 | Moderate | 12 | Polycystic ovarian syndrome | Usual care | Female | 21-32 | 0.53 (-0.58 to 1.64) |
| Vlachopoulou et al. [29] | STAI-S | Moderate | 8 | Chemically dependent | No treatment | Male | 22-43 | -0.75 (-1.76 to 0.26) |
| Vlachopoulou et al. [29] | STAI-T | Moderate | 8 | Chemically dependent | No treatment | Male | 22-43 | 0.82 (-0.20 to 1.83) |
| Zanuso et al. [24] | POMS-T | Vigorous | 12 | Elderly | Wait list | Mixed | 65-78 | 0.07 (-0.81 to 0.94) |
| Zanuso et al. [24] | STAI-T | Vigorous | 12 | Elderly | Wait list | Mixed | 65-78 | -0.08 (-0.96 to 0.80) |

Abbreviations: POMS-T, Profile of Mood States – Tension; SCL-90, Hopkins Symptom Checklist; STAI-T, State-Trait Anxiety Inventory – Trait; STAI-S, State-Trait Anxiety Inventory – State; MHFI-A, Mental Health Functioning Index – Anxiety; HADS-A, Hospital Anxiety and Depression Scales – Anxiety; DASS-21, Depression, Anxiety, and Stress Scale – 21; BRUMS-T, Brunel Mood Scale – Tension; GAD, generalized anxiety disorder; COPD, chronic obstructive pulmonary disease; ES, effect size; CI, confidence intervals

Forest Plot of Unweighted Distribution of Hedges' *d*



Future Research

Clear and complete information regarding adherence, compliance, attendance, session duration, and intensity is needed.

There is a critical lack of studies comparing RET and AET within the same study sample.

Researchers should attempt to match RET with AET as best as possible on multiple relevant features of the exercise stimulus (e.g., intensity/load, time spent actively engaged in exercise, muscle groups exercised).

The evidence regarding the effects of RET among individuals with an anxiety disorder and in those with subclinical levels of anxiety is limited. RCTs of RET effects on anxiety in those with subclinical or prodromal levels of anxiety are needed.

Conclusions

The empirical evidence reviewed herein supports RET as a potential low-risk, alternative or adjuvant therapy for anxiety symptoms.

Future trials should compare RET to other empirically-supported therapies for anxiety, examine plausible neurobiological mechanisms of the anxiolytic effects of RET, and more rigorously examine the optimal total resistance exercise dose required to improve anxiety.

